^Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI (April 1998). "Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease". Hypertension. 31 (4): 906–11. doi:10.1161/01.hyp.31.4.906. PMID9535413.
^Chung DW, Fujikawa K, McMullen BA, Davie EW (August 1986). "Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats". Biochemistry. 25 (9): 2410–7. doi:10.1021/bi00357a017. PMID3521732.
^Page JD, You JL, Harris RB, Colman RW (October 1994). "Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain". Arch. Biochem. Biophys. 314 (1): 159–64. doi:10.1006/abbi.1994.1424. PMID7944388.
Aznar JA, España F, Aznar J, Tascon A, Jimenez C (1978). "Fletcher factor deficiency: report of a new family". Scandinavian Journal of Haematology. 21 (2): 94–8. doi:10.1111/j.1600-0609.1978.tb02498.x. PMID694428.
Henderson LM, Figueroa CD, Muller-Esterl W, Stain A, Bhoola KD (1992). "Immunovisualisation of Plasma Prekallikrein and H-Kininogen on Human Neutrophils and in Human Hepatocytes". In Fritz H, Müller-Esterl W, Jochum M, Roscher A, Luppertz K (eds.). Recent Progress on Kinins. Agents and Actions Supplements. Vol. 38. Birkhäuser. pp. 590–4. doi:10.1007/978-3-0348-7321-5_72 (inactive 1 November 2024). ISBN978-3-0348-7323-9. PMID1466300.{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)
Beaubien G, Rosinski-Chupin I, Mattei MG, Mbikay M, Chrétien M, Seidah NG (1991). "Gene structure and chromosomal localization of plasma kallikrein". Biochemistry. 30 (6): 1628–35. doi:10.1021/bi00220a027. PMID1993180.
McMullen BA, Fujikawa K, Davie EW (1991). "Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule". Biochemistry. 30 (8): 2050–6. doi:10.1021/bi00222a007. PMID1998666.
España F, Berrettini M, Griffin JH (1989). "Purification and characterization of plasma protein C inhibitor". Thromb. Res. 55 (3): 369–84. doi:10.1016/0049-3848(89)90069-8. PMID2551064.
Fujikawa K, Chung DW, Hendrickson LE, Davie EW (1986). "Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry. 25 (9): 2417–24. doi:10.1021/bi00357a018. PMID3636155.
Page JD, You JL, Harris RB, Colman RW (1994). "Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain". Arch. Biochem. Biophys. 314 (1): 159–64. doi:10.1006/abbi.1994.1424. PMID7944388.
Ciechanowicz A, Bader M, Wagner J, Ganten D (1994). "Extra-hepatic transcription of plasma prekallikrein gene in human and rat tissues". Biochem. Biophys. Res. Commun. 197 (3): 1370–6. doi:10.1006/bbrc.1993.2628. PMID8280154.
Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W (1996). "Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor". Biochemistry. 35 (1): 266–72. doi:10.1021/bi951501d. PMID8555184.
Hermann A, Buchinger P, Somlev B, Rehbock J (1996). "High and low molecular weight kininogen and plasma prekallikrein/plasma kallikrein in villous capillaries of human term placenta". Placenta. 17 (4): 223–30. doi:10.1016/S0143-4004(96)90042-9. PMID8761966.
Durham SK, Suwanichkul A, Hayes JD, Herington AC, Powell DR, Campbell PG (1999). "The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis". Horm. Metab. Res. 31 (2–3): 216–25. doi:10.1055/s-2007-978722. PMID10226805. S2CID260169268.
Hermann A, Arnhold M, Kresse H, Neth P, Fink E (1999). "Expression of plasma prekallikrein mRNA in human nonhepatic tissues and cell lineages suggests special local functions of the enzyme". Biol. Chem. 380 (9): 1097–102. CiteSeerX10.1.1.657.2854. doi:10.1515/BC.1999.136. PMID10543447. S2CID15535124.
Cerf M, Raidoo D, Fink E, Fritz H, Bhoola K (2000). "Plasma kallikrein localisation in human blood vessels". Immunopharmacology. 44 (1–2): 75–80. doi:10.1016/S0162-3109(99)00112-5. PMID10604527.
2anw: Expression, crystallization and three-dimensional structure of the catalytic domain of human plasma kallikrein: Implications for structure-based design of protease inhibitors
2any: Expression, Crystallization and the Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein: Implications for Structure-Based Design of Protease Inhibitors